Rakhee Bajaj

Ms. Rakhee Bajaj

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2019 in Nature Communications
Verified
Journal Article
Open access
RMRoxsan Manshouri
Roxsan Manshouri
ECEtienne Coyaud
Etienne Coyaud
SKSamrat T. Kundu
Samrat T. Kundu
DPDavid H. Peng
David H. Peng
SSSabrina A. Stratton
Sabrina A. Stratton
DGDon L. Gibbons
Don L. Gibbons
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, due in part to the propensity of lung cancer to metastasize. Aberrant epithelial-to-mesenchymal transition (EMT) is a proposed model for the initiation of metastasis. During EMT cell-cell adhesion is reduced allowing cells to dissociate and invade. Of the EMT-associated transcription factors, ZEB1 uniquely promotes NSCLC disease progression. Here we apply two independent screens, BioID and an Epigenome shRNA dropout screen, to define ZEB1 interactors that are critical to metastatic NSCLC. We identify the NuRD complex as a ZEB1 co-repressor and the Rab22 GTPase-activating protein TBC1D2b as a ZEB1/NuRD complex target. We find that TBC1D2b suppresses E-cadherin internalization, thus hindering cancer cell invasion and metastasis.

28 April 2022 in Cells
Verified
Journal Article
Open access
PDF file
RBRakhee Bajaj
Rakhee Bajaj
AWAmanda Warner
Amanda Warner
JFJared Joseph-Alan Fradette
Jared Joseph-Alan Fradette
DGDon L. Gibbons
Don L. Gibbons
The Golgi apparatus is at the center of protein processing and trafficking in normal cells. Under pathological conditions, such as in cancer, aberrant Golgi dynamics alter the tumor microenvironment and the immune landscape, which enhances the invasive and metastatic potential of cancer cells. Among these changes in the Golgi in cancer include altered Golgi orientation and morphology that contribute to atypical Golgi function in protein trafficking, post-translational modification, and exocytosis. Golgi-associated gene mutations are ubiquitous across most cancers and are responsible for modifying Golgi function to become pro-metastatic. The pharmacological targeting of the Golgi or its associated genes has been difficult in the clinic; thus, studying the Golgi and its role in cancer is critical to developing novel therapeutic agents that limit cancer progression and metastasis. In this review, we aim to discuss how disrupted Golgi function in cancer cells promotes invasion and metastasis.

4 August 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
RBRakhee Bajaj
Rakhee Bajaj
SKSamrat Kundu
Samrat Kundu
CGCaitlin L. Grzeskowiak
Caitlin L. Grzeskowiak
JFJared Joseph-Alan Fradette
Jared Joseph-Alan Fradette
KSKenneth L. Scott
Kenneth L. Scott
DGDon L. Gibbons
Don L. Gibbons

27 September 2022 in Cell Reports
Verified
Journal Article
Open access
RBRakhee Bajaj
Rakhee Bajaj
BRB. Leticia Rodriguez
B. Leticia Rodriguez
WRWilliam K. Russell
William K. Russell
AWAmanda N. Warner
Amanda N. Warner
LDLixia Diao
Lixia Diao
DGDon L. Gibbons
Don L. Gibbons
Lung cancer is a highly aggressive and metastatic disease responsible for approximately 25% of all cancer-related deaths in the United States. Using high-throughput in vitro and in vivo screens, we have previously established Impad1 as a driver of lung cancer invasion and metastasis. Here we elucidate that Impad1 is a direct target of the epithelial microRNAs (miRNAs) miR-200 and miR~96 and is de-repressed during epithelial-to-mesenchymal transition (EMT); thus, we establish a mode of regulation of the protein. Impad1 modulates Golgi apparatus morphology and vesicular trafficking through its interaction with a trafficking protein, Syt11. These changes in Golgi apparatus dynamics alter the extracellular matrix and the tumor microenvironment (TME) to promote invasion and metastasis. Inhibiting Impad1 or Syt11 disrupts the cancer cell secretome, regulates the TME, and reverses the invasive or metastatic phenotype. This work identifies Impad1 as a regulator of EMT and secretome-mediated changes during lung cancer progression.

22 September 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
JOJoshua Kapere Ochieng
Joshua Kapere Ochieng
SKSamrat Kundu
Samrat Kundu
RBRakhee Bajaj
Rakhee Bajaj
BRB. Leticia Rodriguez
B. Leticia Rodriguez
JFJared Joseph-Alan Fradette
Jared Joseph-Alan Fradette
DGDon L. Gibbons
Don L. Gibbons